Publications
Interplay Between Oncomicrobes, the Microbiota and the Immune System: Impact on Responses to Cancer Immunotherapy
Cancer immunotherapies harness the power of the immune system to target cancer cells that express tumor-associated antigens. Immune checkpoint inhibitors, such as monoclonal antibodies against inhibitory T cell receptors, i.e., PD-1/PD-L1 and CTLA-4, allow cancer...
Combined Microbiome and Metabolome Analysis Reveals a Novel Interplay Between Intestinal Flora and Serum Metabolites in Lung Cancer
As the leading cause of cancer death, lung cancer seriously endangers human health and quality of life. Although many studies have reported the intestinal microbial composition of lung cancer, little is known about the interplay between intestinal microbiome and...
Alterations of lung microbiota in patients with non-small cell lung cancer
The role of lung microbiota in non-small cell lung cancer remains unclear. We investigated the characteristics and functional roles of lung microbiota in non-small cell lung cancer.Bronchoalveolar lavage fluid samples were obtained from patients with non-small cell...
The composition of lung microbiome in lung cancer: a systematic review and meta-analysis
Background: Although recent studies have indicated that imbalance in the respiratory microbiome composition is linked to several chronic respiratory diseases, the association between the lung microbiome and lung cancer has not been extensively studied. Conficting...
Microbiome dysbiosis in lung cancer: from composition to therapy
The correlations between microbiota dysbiosis and cancer have gained extensive attention and been widely explored. As a leading cancer diagnosis worldwide, lung cancer poses a great threat to human health. The healthy human lungs are consistently exposed to external...
Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes
Despite the promising advances in novel cancer therapy such as immune checkpoint inhibitors (ICIs), limitations including therapeutic resistance and toxicity remain. In recent years, the relationship between gut microbiota and cancer has been extensively studied....
Metagenomic Analyses Reveal Distinct Gut Microbiota Signature for Predicting the Neoadjuvant Chemotherapy Responsiveness in Breast Cancer Patients
Growing evidence supports the modulatory role of human gut microbiome on neoadjuvant chemotherapy (NAC) efficacy. However, the relationships among the gut microbiome, tumor-infiltrating lymphocytes (TILs), and NAC response for breast cancer (BC) patients remain unclear. We thus proposed this preliminary study to investigate the relationship between gut microbiome and BC patients’ responses to NAC treatment as well as underlying mechanisms.
Deciphering the Microbiome-Immunity-Cancer Axis
Trillions of microbes inhabit human body surfaces and cavities and interact with the host constantly. Recently, it came to light that the microbiota is a critical regulator of tumorigenesis and impacts outcomes of various cancer therapies.
Targeting the gut and tumor microbiota in cancer
Microorganisms within the gut and other niches may contribute to carcinogenesis, as well as shaping cancer immunosurveillance and response to immunotherapy.
